non‑Hodgkin’s lymphoma	is a	cancer
non‑Hodgkin’s lymphoma	is a	lymphoid malignancy
non‑Hodgkin’s lymphoma	originates from	B‑cells
non‑Hodgkin’s lymphoma	originates from	T‑cells
non‑Hodgkin’s lymphoma	is classified by	WHO system
non‑Hodgkin’s lymphoma	is staged by	Ann Arbor staging
non‑Hodgkin’s lymphoma	is treated with	chemotherapy
non‑Hodgkin’s lymphoma	is treated with	radiation therapy
non‑Hodgkin’s lymphoma	is treated with	immunotherapy
non‑Hodgkin’s lymphoma	is treated with	targeted therapy
non‑Hodgkin’s lymphoma	is treated with	stem cell transplant
non‑Hodgkin’s lymphoma	responds to	rituximab
non‑Hodgkin’s lymphoma	responds to	obinutuzumab
non‑Hodgkin’s lymphoma	responds to	brentuximab
non‑Hodgkin’s lymphoma	responds to	lenalidomide
non‑Hodgkin’s lymphoma	responds to	bortezomib
non‑Hodgkin’s lymphoma	is associated with	HIV infection
non‑Hodgkin’s lymphoma	is associated with	EBV infection
non‑Hodgkin’s lymphoma	is associated with	autoimmune disease
non‑Hodgkin’s lymphoma	is associated with	immunosuppression
non‑Hodgkin’s lymphoma	is associated with	organ transplant
non‑Hodgkin’s lymphoma	is associated with	smoking
non‑Hodgkin’s lymphoma	is associated with	obesity
non‑Hodgkin’s lymphoma	is associated with	chronic inflammation
non‑Hodgkin’s lymphoma	is associated with	genetic mutation
non‑Hodgkin’s lymphoma	is associated with	chromosomal translocation
non‑Hodgkin’s lymphoma	is associated with	MYC translocation
non‑Hodgkin’s lymphoma	is associated with	BCL2 translocation
non‑Hodgkin’s lymphoma	is associated with	BCL6 translocation
non‑Hodgkin’s lymphoma	is associated with	TP53 mutation
non‑Hodgkin’s lymphoma	is associated with	NOTCH1 mutation
non‑Hodgkin’s lymphoma	is associated with	EZH2 mutation
non‑Hodgkin’s lymphoma	is associated with	CARD11 mutation
non‑Hodgkin’s lymphoma	is associated with	NF‑κB activation
non‑Hodgkin’s lymphoma	is associated with	PI3K‑AKT pathway
non‑Hodgkin’s lymphoma	is associated with	JAK‑STAT pathway
non‑Hodgkin’s lymphoma	is associated with	MYD88 mutation
non‑Hodgkin’s lymphoma	is associated with	CD79B mutation
non‑Hodgkin’s lymphoma	is associated with	T‑cell receptor rearrangement
non‑Hodgkin’s lymphoma	is associated with	immunoglobulin heavy chain
non‑Hodgkin’s lymphoma	is associated with	CD20 expression
non‑Hodgkin’s lymphoma	is associated with	CD30 expression
non‑Hodgkin’s lymphoma	is associated with	CD5 expression
non‑Hodgkin’s lymphoma	is associated with	CD10 expression
non‑Hodgkin’s lymphoma	is associated with	Ki‑67 proliferation
non‑Hodgkin’s lymphoma	is associated with	lactate dehydrogenase elevation
non‑Hodgkin’s lymphoma	is associated with	B‑cell receptor signaling
non‑Hodgkin’s lymphoma	is associated with	T‑cell receptor signaling
non‑Hodgkin’s lymphoma	is associated with	tumor microenvironment
non‑Hodgkin’s lymphoma	is associated with	PD‑L1 expression
non‑Hodgkin’s lymphoma	is associated with	immune checkpoint inhibition
non‑Hodgkin’s lymphoma	is associated with	CAR‑T therapy
non‑Hodgkin’s lymphoma	is associated with	bispecific T‑cell engager
non‑Hodgkin’s lymphoma	is associated with	antibody‑drug conjugate
non‑Hodgkin’s lymphoma	is associated with	clinical trial enrollment
non‑Hodgkin’s lymphoma	is associated with	relapse risk
non‑Hodgkin’s lymphoma	is associated with	refractory disease
non‑Hodgkin’s lymphoma	is associated with	high‑grade histology
non‑Hodgkin’s lymphoma	is associated with	low‑grade histology
non‑Hodgkin’s lymphoma	is associated with	nodal disease
non‑Hodgkin’s lymphoma	is associated with	extranodal disease
non‑Hodgkin’s lymphoma	is associated with	bulky disease
non‑Hodgkin’s lymphoma	is associated with	B‑symptoms
non‑Hodgkin’s lymphoma	is associated with	anemia
non‑Hodgkin’s lymphoma	is associated with	thrombocytopenia
non‑Hodgkin’s lymphoma	is associated with	neutropenia
non‑Hodgkin’s lymphoma	is associated with	hypercalcemia
non‑Hodgkin’s lymphoma	is associated with	renal dysfunction
non‑Hodgkin’s lymphoma	is associated with	CNS involvement
non‑Hodgkin’s lymphoma	is associated with	bone marrow infiltration
non‑Hodgkin’s lymphoma	is associated with	PET‑CT positivity
non‑Hodgkin’s lymphoma	is associated with	CT scan abnormality
non‑Hodgkin’s lymphoma	is associated with	MRI abnormality
non‑Hodgkin’s lymphoma	is associated with	ultrasound abnormality
non‑Hodgkin’s lymphoma	is associated with	biopsy requirement
non‑Hodgkin’s lymphoma	is associated with	flow cytometry
non‑Hodgkin’s lymphoma	is associated with	immunohistochemistry
non‑Hodgkin’s lymphoma	is associated with	cytogenetic analysis
non‑Hodgkin’s lymphoma	is associated with	next‑generation sequencing
non‑Hodgkin’s lymphoma	is associated with	prognostic score
non‑Hodgkin’s lymphoma	is associated with	International Prognostic Index
non‑Hodgkin’s lymphoma	is associated with	Revised International Prognostic Index
non‑Hodgkin’s lymphoma	is associated with	age factor
non‑Hodgkin’s lymphoma	is associated with	performance status
non‑Hodgkin’s lymphoma	is associated with	comorbidity index
non‑Hodgkin’s lymphoma	is associated with	treatment toxicity
non‑Hodgkin’s lymphoma	is associated with	quality of life
non‑Hodgkin’s lymphoma	is associated with	survival outcome
non‑Hodgkin’s lymphoma	is associated with	overall survival
non‑Hodgkin’s lymphoma	is associated with	progression‑free survival
non‑Hodgkin’s lymphoma	is associated with	relapse‑free survival
non‑Hodgkin’s lymphoma	is associated with	hospitalization risk
non‑Hodgkin’s lymphoma	is associated with	readmission risk
non‑Hodgkin’s lymphoma	is associated with	cost burden
non‑Hodgkin’s lymphoma	is associated with	insurance coverage
non‑Hodgkin’s lymphoma	is associated with	clinical guideline
non‑Hodgkin’s lymphoma	is associated with	NCCN recommendations
non‑Hodgkin’s lymphoma	is associated with	ESMO guidelines
non‑Hodgkin’s lymphoma	is associated with	patient education
non‑Hodgkin’s lymphoma	is associated with	survivorship care
